Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Broad molecular screening of an unclassifiable myeloproliferative disorder reveals an unexpected ETV6/ABL1 fusion transcript

Leukemia volume 19, pages 1096–1099 (2005)Cite this article

TO THE EDITOR

Fusion transcripts are a key element in leukemogenesis. A large number of recurrent chromosomal translocations have been defined, some of which are integrated in the WHO classification of leukemias. Targeted therapies using all-trans-retinoic acid in acute promyelocytic leukemias or the tyrosine kinase inhibitor Imatinib Mesylate in CML have revolutionized the treatment strategies in malignant hematologic diseases.1 Imatinib has been shown to inhibit the tyrosine kinase activity of BCR/ABL, but also of an increasing number of other tyrosine kinases such as ETV6/PDGFRb, c-Kit and FIP1L1-PDGFRa.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

References

  1. Wadleigh M, Deangelo DJ, Griffin JD, Stone RM . After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood 2005; 105: 22–30 (Epub 2004 September 09).

    Article  CAS  Google Scholar 

  2. Hannemann JR, McManus DM, Kabarowski JH, Wiedemann LM . Haemopoietic transformation by the TEL/ABL oncogene. Br J Haematol 1998; 102: 475–485.

    Article  CAS  Google Scholar 

  3. Andreasson P, Johansson B, Carlsson M, Jarlsfelt I, Fioretos T, Mitelman F et al. BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion. Genes Chromosomes Cancer 1997; 20: 299–304.

    Article  CAS  Google Scholar 

  4. Barbouti A, Ahlgren T, Johansson B, Hoglund M, Lassen C, Turesson I et al. Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate. Br J Haematol 2003; 122: 85–93.

    Article  CAS  Google Scholar 

  5. La Starza R, Trubia M, Testoni N, Ottaviani E, Belloni E, Crescenzi B et al. Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia. Haematologica 2002; 87: 789–794.

    PubMed  Google Scholar 

  6. Keung YK, Beaty M, Steward W, Jackle B, Pettnati M . Chronic myelocytic leukemia with eosinophilia, t(9;12)(q34;p13), and ETV6-ABL gene rearrangement: case report and review of the literature. Cancer Genet Cytogenet 2002; 138: 139–142.

    Article  CAS  Google Scholar 

  7. Million RP, Aster J, Gilliland DG, Van Etten RA . The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. Blood 2002; 99: 4568–4577.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank Heike Huxol for the excellent technical assistance for the RT-PCR. We are also grateful to Sandrine Bougeon, Ornella Bruzzese, Danielle Ahmad and Christelle Saporita for expert technical assistance for the cytogenetic preparations, Anne-Claude Gaide and Marianne Wicht for the determination of the constitutional karyotype and P Marynen and A Hagemeijer-Hausmann, Leuven, for providing us with the cosmid probes. We also would like to thank Regine Landmann for carefully reading the manuscript.

Author information

Authors and Affiliations

  1. Hematology, University Hospital, Basel, Switzerland

    S Meyer-Monard, A Gratwohl & A Tichelli

  2. Unité de Cytogénétique du cancer, Service de génétique médicale, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

    D Mühlematter & M Jotterand

  3. Kantonsspital, Baden, Switzerland

    A Streit

  4. Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, UK

    A J Chase & N C P Cross

Authors
  1. S Meyer-Monard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Mühlematter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Streit
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A J Chase
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Gratwohl
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N C P Cross
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Jotterand
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Tichelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Meyer-Monard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meyer-Monard, S., Mühlematter, D., Streit, A. et al. Broad molecular screening of an unclassifiable myeloproliferative disorder reveals an unexpected ETV6/ABL1 fusion transcript. Leukemia 19, 1096–1099 (2005). https://doi.org/10.1038/sj.leu.2403697

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403697

This article is cited by

Search

Advanced search

Quick links